天津医药

天津医药 ›› 2017, Vol. 45 ›› Issue (4): 402-405.doi: 10.11958/20170063

• 临床研究 • 上一篇    下一篇

宫颈癌中 MST1 蛋白的表达及临床意义

郑小影 1， 郝云涛 2， 赵淑敏 1△， 刘美娜 3， 梁秀军 1   

  1. 1 承德医学院基础医学院 （邮编 067000）； 2 承德医学院附属医院妇科； 3 滦平县医院麻醉科
  • 收稿日期:2017-01-13 修回日期:2017-03-14 出版日期:2017-04-15 发布日期:2017-04-15
  • 通讯作者: △通讯作者 E-mail: zhaoshumin-2008@163.com E-mail:zhengxiaoying0415@163.com
  • 作者简介:郑小影 （1980）， 女， 硕士研究生， 主要从事肿瘤病理研究
  • 基金资助:
    河北省卫计委医学科学研究重点课题计划项目 （20150015）； 承德市科技局科学研究与发展计划项目 （20122148， 20142031）

Expression and clinical significance of MST1 in cervical cancer

ZHENG Xiao-ying1, HAO Yun-tao2, ZHAO Shu-min1△, LIU Mei-na3, LIANG Xiu-jun1   

  1. 1 Basic Medical College of Chengde Medical College, Chengde 067000, China; 2 Department of Gynecology, the Affiliated
    Hospital of Chengde Medical College; 3 Department of Anesthesiology, Luanping County Hospital
  • Received:2017-01-13 Revised:2017-03-14 Published:2017-04-15 Online:2017-04-15
  • Contact: △Corresponding Author E-mail: zhaoshumin-2008@163.com E-mail:zhengxiaoying0415@163.com

PDF (PC)

4526

摘要： 目的 探讨哺乳动物不育系 20 样激酶 1 （MST1） 在宫颈癌中的表达及其临床意义。方法 应用免疫组织 化学实验检测 139 例宫颈癌组织及 20 例癌旁组织（距离肿瘤≥4 cm）标本中 MST1 蛋白表达情况， Western blot 和 qPCR 分别检测 20 例宫颈癌及其配对癌旁组织中 MST1 蛋白及 mRNA 表达水平， 并分析其表达与临床病理因素及 预后之间的关系。结果 MST1 主要表达在细胞质。宫颈癌组织中 MST1 的表达阳性率（27%， 38/139）明显低于癌 旁组织 （80%， 16/20）， 差异有统计学意义 （χ2=21.62， P < 0.01）， 且宫颈癌组织 MST1 蛋白及 mRNA 表达水平均明显降 低 （P < 0.01）。Ⅰb+Ⅱa 期的宫颈癌患者 MST1 阳性表达率高于Ⅱb+Ⅳ期， 有淋巴结转移者 MST1 阳性表达率低于无 淋巴结转移者（均 P < 0.05）； 患者年龄、 肿瘤直径、 组织学分型及分化程度对 MST1 阳性表达率无影响。MST1 阴性 表达患者的生存时间较阳性表达者显著缩短（Log-rank χ2=28.35， P < 0.01）。结论 MST1 在宫颈癌中呈低表达， 可 能是宫颈癌临床治疗和判断预后的新靶点。

关键词: 宫颈肿瘤, 预后, 哺乳动物不育系 20 样激酶 1, 表达, 临床特征, 生存分析

Abstract: Objective To investigate the expression and clinical significance of mammalian sterile 20-like kinase 1 (MST1) in cervical cancer. Methods Immunohistochemical method was applied to detect the expression level of MST1 protein in specimens of cervical cancer tissues (n=139) and pericarcinomatous tissues (n=20, with ≥4 cm distance from the primary tumor’ s edge). Western blot assay and qPCR were used to detect the protein and mRNA transcription expression levels of MST1 in 20 pairs of cervical cancer tissues and pericarcinomatous tissues, respectively. The correlation between MST1 expression, clinic pathological features and the prognosis were analyzed. Results MST1 was mainly expressed in cytoplasm. The positive expression rate of MST1 was significantly lower in cervical cancer tissues (27%, 38/139) than that in pericarcinomatous tissues (80%, 16/20, χ2=21.62, P < 0.01). The expressions levels of MST1 protein and mRNA were both lower in the cervical cancer tissues (P < 0.01). In cervical cancer, the positive expression rate of MST1 in Ⅰb+Ⅱa stage was higher than that of Ⅱb+Ⅳ stage (P < 0.05), the positive expression rate of MST1 in lymph node metastasis was lower than that of without lymph node metastasis (P < 0.05). Values of age, tumor size, histological type and differentiation degree showed no significant difference to positive expression rate of MST1. Moreover, the negative expression of MST1 displayed a significantly poorer overall survival time than that of positive expression of MST1 (Log- rank χ2=28.35, P < 0.01). Conclusion MST1 shows a lower expression in cervical cancer, which may be a new target for clinical treatment and prognosis of cervical cancer.

Key words: uterine cervical neoplasms, prognosis, MST1, expression, clinical characteristic, survival analysis